Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

This study consists of a screening study and 3 different Antibody-Drug Conjugate (ADC) treatment substudies. The screening steps will determine whether you are eligible to participate in an ADC treatment substudy. If the screening testing result shows that your tumor has an ADC target that matches a specific available substudy, you will be eligible to participate in that substudy. Each available substudy will test a different targeted treatment called an Antibody-Drug Conjugate (ADC). ADCs are antibodies that target proteins on cancer cells and are linked to chemotherapy. ADCs help chemotherapy to specifically target cancer cells. The three possible ADC treatments are: sacituzumab govitecan (IMMU-132), enfortumab vedotin- ejfv, and trastuzumab deruxtecan (DS-8201a). Each ADC substudy will evaluate the good and bad effects of the ADC treatment, and whether the treatment can lower the chance of cancer growing.

Are you Eligible? (Inclusion Criteria)

• The following inclusion criteria must be met for you to participate in the screening study. The screening study will then determine whether you are eligible to participate in a treatment substudy. - Are you 18 years of age or older? - Have you been diagnosed with a solid tumor that requires treatment? - Are you willing to come to the clinic for regularly scheduled treatment and evaluations, including biopsies performed for research purposes?